New England Compounding Center Recalls Isovue Vials Due to Sterility Concerns
New England Compounding Center is recalling Isovue 200 mg/mL and 300 mg/mL vials nationwide due to a lack of assurance of sterility.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a 'Severe' rating under the rubric, particularly given the risk of infection associated with non-sterile medical products.
Plain-English summary
New England Compounding Center, located in Framingham, Massachusetts, is recalling Isovue 200 mg/mL PF and 300 mg/mL PF vials. The recall involves 7,055 vials distributed nationwide. The reason for the recall is a lack of assurance of sterility.
The source text does not specify particular lot codes, stating that all lot codes are affected. No specific dates of distribution or manufacturing are provided in the notice.
Consumers and healthcare providers should stop using the affected vials and contact their supplier or the manufacturer for further instructions on returns or replacements.
The recalled product
- Product
- Isovue 200 mg/mL PF and 300 mg/mL PF, Vials, manufactured by New England Compounding Center, Framingham, MA
- Manufacturer
- New England Compounding Center
- Category
- Drug — Injectable Contrast Media
- Affected units
- 7,055
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lot codes
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 17 recalled by New England Compounding Center under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 17 products in this recall →Related recalls
Same manufacturer · New England Compounding Center
See all →- SevereNew England Compounding Center Recalls Lidocaine Vials Due to Sterility Concerns
FDA (Drugs) · 2013-01-09
- SevereNew England Compounding Center Recalls Lidocaine Dextrose Due to Sterility Concerns
FDA (Drugs) · 2013-01-09
- HighNew England Compounding Center Recalls Triamcinolone Vials Due to Sterility Concerns
FDA (Drugs) · 2013-01-09
- CriticalFDA Recalls Methylprednisolone Acetate Injection Due to Non-Sterility
FDA (Drugs) · 2013-01-09
- CriticalFDA Recalls Methylprednisolone Acetate Injection Due to Non-Sterility
FDA (Drugs) · 2013-01-09
Same hazard · lack of sterility
See all →- HighRohto Cooling Eye Drops Max Strength Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- HighRohto Cooling Eye Drops Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2026-07-29
- SevereCleviprex Injectable Emulsion Recall Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-07-22
- SeverePemetrexed for Injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-07-15
- SevereAzacitidine for Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15